专访诺力昂副总裁David Freidinger，深入了解色谱纯化填料界的瑞典“巨人”Kromasil®

Core Viewpoint - The article discusses the significant role of Kroma sil® in the pharmaceutical industry, emphasizing its advanced chromatography solutions that enhance drug purification efficiency and stability, particularly in the context of rising demand for GLP-1 receptor agonists and other innovative therapies [2][11]. Group 1: Industry Trends - The global pharmaceutical market is undergoing rapid transformation, driven by increasing prevalence of lifestyle diseases such as type 2 diabetes and obesity, which in turn boosts the demand for targeted therapeutic drugs [2][11]. - Local pharmaceutical companies are shifting from generic drug production to innovative drug development as patent expirations approach, creating a competitive landscape for advanced purification solutions [2][11]. Group 2: Company Overview - Nouryon is a global specialty chemicals company operating in over 80 countries, with a workforce of more than 8,200 employees, serving various sectors including personal care, pharmaceuticals, and agriculture [3]. - Kroma sil® has been dedicated to the development and production of high-purity silica gel chromatography media since 1988, leveraging over 30 years of technological expertise to address modern drug purification challenges [2][5]. Group 3: Product and Technology - Kroma sil® products are designed to reduce drug purification costs significantly, with the ability to lower costs by over 70% in insulin production processes due to their longer lifespan and higher sample loading capacity [5][7]. - The product line includes various pore sizes (60Å, 100Å, 300Å) and particle sizes (1.8 to 13 microns), catering to a wide range of purification needs from small molecules to large biomolecules [7]. Group 4: Customer Needs and Solutions - Key customer requirements in the pharmaceutical sector include stability and scalability of chromatography media, which Kroma sil® addresses through its robust mechanical strength and chemical stability [8][9]. - The company employs a "same factory, same process" strategy to ensure consistency in chromatography media across different production scales, facilitating seamless scale-up from laboratory to industrial production [9][10]. Group 5: Market Strategy and Growth - Kroma sil® is focusing on expanding its capacity and technological innovation to meet the growing demand for GLP-1 receptor agonists, with plans to double production capacity by early 2027 [11][12]. - The company is committed to deepening its presence in the Chinese market, collaborating with local enterprises to develop customized purification solutions that align with domestic policies and market needs [13]. Group 6: Competitive Advantage - Kroma sil®'s competitive edge lies in its technological leadership and extensive experience, having accumulated nearly 40 years of collaboration with major pharmaceutical companies, which provides valuable insights for local firms [10][13]. - The company remains optimistic about the long-term growth prospects in the pharmaceutical sector, viewing it as one of the most attractive growth areas despite short-term market fluctuations [13].